Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis

Blood

Volumn 111, Issue 8, 2008, Pages 4322-4328

  Balgobind, Brian V ^a   Van Vlierberghe, Pieter ^a   Van Den Ouweland, Ans M W ^b   Beverloo, H Berna ^b   Terlouw Kromosoeto, Joan N R ^b   Van Wering, Elisabeth R ^c   Reinhardt, Dirk ^d   Horstmann, Martin ^e   Kaspers, Gertjan J L ^f   Pieters, Rob ^a   Zwaan, C Michel ^a   Van Den Heuvel Eibrink, Marry M ^a   Meijerink, Jules P P ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c DCOG Dutch Childhood Oncology Group   (Netherlands)

^d Acute Myeloid Leukemia Berlin Frankfurt Munster (AML BFM) Study Group   (Germany)

^e German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia (COALL)   (Germany)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; NEUROFIBROMIN; RNA; TRANSCRIPTION FACTOR TAL1; MESSENGER RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLELE; ARTICLE; CANCER GROWTH; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE EXPRESSION; GENE IDENTIFICATION; GENE INACTIVATION; GENE MUTATION; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; NEUROFIBROMATOSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; ADOLESCENT; CHILD; GENE EXPRESSION REGULATION; GENE REARRANGEMENT; GENETICS; METABOLISM; MOLECULAR GENETICS; MUTATION; NUCLEIC ACID AMPLIFICATION; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; T CELL LEUKEMIA LYMPHOMA;

ADOLESCENT; BASE SEQUENCE; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GENE REARRANGEMENT; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MALE; MOLECULAR SEQUENCE DATA; MUTATION; NEUROFIBROMATOSES; NEUROFIBROMIN 1; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RNA, MESSENGER; SEQUENCE DELETION;

EID: 43249089608     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-06-095075     Document Type: Article

References (39)

1. Theos A, Korf BR. Pathophysiology of neurofibromatosis type 1. Ann Intern Med. 2006;144:842-849.
2. Jenne DE, Tinschert S, Stegmann E, et al. Acommon set of at least 11 functional genes is lost in the majority of NF1 patients with gross deletions. Genomics. 2000;66:93-97.
3. Jenne DE, Tinschert S, Reimann H, et al. Molecular characterization and gene content of breakpoint boundaries in patients with neurofibromatosis type 1 with 17q11.2 microdeletions. Am J Hum Genet. 2001;69:516-527.
4. Kai S, Sumita H, Fujioka K, et al. Loss of heterozygosity of NF1 gene in juvenile chronic myelogenous leukemia with neurofibromatosis type 1. Int J Hematol. 1998;68:53-60.
5. Side L, Taylor B, Cayouette M, et al. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med. 1997;336:1713-1720.
6. Flotho C, Steinemann D, Mullighan CG, et al. Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11. Oncogene. 2007;26:5816-5821.
7. Side LE, Emanuel PD, Taylor B, et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood. 1998;92:267-272.
8. Le DT, Kong N, Zhu Y, et al. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood. 2004;103:4243-4250.
9. McCormick F. Ras signaling and NF1. Gurr Opin Genet Dev. 1995;5:51-55.
10. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532-1542.
11. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial: the Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322-2333.
12. Raimondi SC, Chang MN, Ravindranath Y, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood. 1999;94:3707-3716.
13. Eguchi M, Eguchi-lshimae M, Knight D, Kearney L, Slany R, Greaves M. MLL chimeric protein activation renders cells vulnerable to chromosomal damage: an explanation for the very short latency of infant leukemia. Genes Chromosomes Cancer. 2006;45:754-760.
14. Rubnitz JE, Raimondi SC, Tong X, et al. Favorable impact of the t(9; 11) in childhood acute myeloid leukemia. J Clin Oncol. 2002;20:2302-2309.
15. Lie SO, Abrahamsson J, Clausen N, et al. Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials. Br J Haematol. 2003;122:217-225.
16. Palle J, Frost BM, Forestier E, et al. Cellular drug sensitivity in MLL-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage. Br J Haematol. 2005;129:189-198.
17. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350:1535-1548.
18. De Keersmaecker K, Marynen P, Cools J. Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia. Haematologica. 2005;90:1116-1127.
19. Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol. 2005;23:6306-6315.
20. Grabher C, von Boehmer H, Look AT. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer. 2006;6:347-359.
21. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T-cell acute lymphoblastic leukemia. Science. 2004;306:269-271.
22. Breit S, Stanulla M, Flohr T, et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood. 2006;108:1151-1157.
23. Thompson BJ, Buonamici S, Sulis ML, et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T-cell leukemia. J Exp Med. 2007;204:1825-1835.
24. O'Neil J, Grim J, Strack P, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med. 2007;204:1813-1824.
25. Van Vlierberghe P, van Grotel M, Beverloo HB, et al. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LM02 in pediatric T-cell acute lymphoblastic leukemia. Blood. 2006;108:3520-3529.
26. Barrett MT, Scheffer A, Ben-Dor A, et al. Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. Proc Natl Acad Sci U S A. 2004;101:17765-17770.
27. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002;30:e57.
28. Wimmer K, Yao S, Claes K, et al. Spectrum of single- and multiexon NF1 copy number changes in a cohort of 1,100 unselected NF1 patients. Genes Chromosomes Cancer. 2006;45:265-276.
29. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97:2434-2439.
30. Kiyoi H, Naoe T, Yokota S, et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia: Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia. 1997;11:1447-1452.
31. Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004;351:533-542.
32. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446:758-764.
33. Kehrer-Sawatzki H, Kluwe L, Sandig C, et al. High frequency of mosaicism among patients with neurofibromatosis type 1 (NF1) with microdeletions caused by somatic recombination of the JJAZ1 gene. Am J Hum Genet. 2004;75:410-423.
34. Petek E, Jenne DE, Smolle J, et al. Mitotic recombination mediated by the JJAZF1 (KIAA0160) gene causing somatic mosaicism and a new type of constitutional NF1 microdeletion in two children of a mosaic female with only few manifestations. J Med Genet. 2003;40:520-525.
35. Raedt TD, Stephens M, Heyns I. et al. Conservation of hotspots for recombination in low-copy repeats associated with the NF1 microdeletion. Nat Genet. 2006;38:1419-1423.
36. Barkan B, Starinsky S, Friedman E, Stein R, Kloog Y. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1. Clin Cancer Res. 2006;12:5533-5542.
37. Graux C, Cools J, Michaux L, Vandenberghe P, Hagemeijer A. Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia. 2006;20:1496-1510.
38. Fitzgibbon J, Smith LL, Raghavan M, et al. Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res. 2005;65:9152-9154.
39. Raghavan M, Lillington DM, Skoulakis S, et al. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res. 2005;65:375-378.